Leflunomide and methotrexate

Current Opinion in Rheumatology

Volumn 13, Issue 3, 2001, Pages 159-163

  Laan, Roland F J M ^a,b   Van Riel, Piet L C M ^a   Van De Putte, Leo B A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE;

ALOPECIA; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; NAUSEA; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; METHOTREXATE; TREATMENT OUTCOME;

EID: 0035022323     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200105000-00002     Document Type: Review

References (18)

1. 1 Smolen JS, Kalden JR, Scott DL, et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicenter trial. Lancet 1999, 353:259-266.
2. 2 Strand V, Cohen S, Schiff M, et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999, 159:2542-2550.
3. 3 Emery P, Breedveld FC, Lemmel EM, et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000, 39:656-665. These three excellent studies provide the key clinical data on efficacy and toxicity of leflunomide in comparison to placebo, sulfasalazine, and methotrexate.
4. 4 Strand V, Tugwell P, Bombardier C, et al.: Function and health-related quality of life. Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999, 42:1870-1878.
5. 5 Sharp J, Strand V, Leung H, et al.: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000, 43:495-505.
6. 6 Janssen N, Genta MS: The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000, 160:610-619.
7. 7 Furst DE: The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997, 36:1196-1204.
8. 8 Van Ede AE, Laan RFJM, Blom HJ, et al.: Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998, 27:277-292.
9. 9 Ortiz Z, Shea B, Suarez-Almazor ME, et al.: The efficacy of folic and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a meta-analysis of randomized controlled trials. J Rheumatol 1998, 25:36-43.
10. 10 Schiff MH: Leflunomide versus methotrexate: A comparison of the European and American experience. Scand J Rheumatol 1999, 28 (suppl 112):31-35.
11. 11 Strand V, Morgan SL, Baggott JE et al.: Folic acid supplementation and methotrexate efficacy: comment on the articles by Schiff, Emery et al, and others. Arthritis Rheum 2000, 43:2615-2616.
12. 12 Wluka A, Buchbinder R, Mylvaganam A, et al.: Long-term methotrexate use in rheumatoid arthritis: 12 year follow-up of 460 patients treated in community practice. J Rheumatol 2000, 27:1864-1871.
13. 13 Fox RI, Herrmann ML, Frangou CG, et al.: Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999, 93:198-208.
14. 14 Breedveld FC, Dayer JM: Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000, 59:841-849. Excellent review of possible immunomodulatory actions of leflunomide in the treatment of rheumatoid arthritis at the cellular and molecular levels. In addition, the authors provide a clinical overview of efficacy and safety of the drug and possibilities for combination therapy.
15. 15 Manna SK, Aggarwal BB: Immunosuppressive leflunomide metabolite (A771726) blocks TNF-dependent nuclear factor κB activation and gene expression. J Immunol 1999, 162:2095-2102.
16. 16 Manna SK, Mukhopadhyay A, Aggarwal BB: Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappaB, Activator protein-1, c-Jun N-terrninal protein kinase, and apoptosis. J Immmunol 2000, 165:5962-5969.
17. 17 Kraan MC, de Koster BM, Elferink JG, et al.: Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum 2000, 43:1488-1495.
18. 18 Kraan MC, Reece RJ, Barg EC, et al.: Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000, 43:1820-1830.